Once a covered equity is enrolled in the 340B Program and included in the covered entities database, it is the covered entity's responsibility to inform wholesalers and manufacturers of enrollment in order to purchase drugs at the 340B discounted price.
Covered entities may continue to work directly with individual wholesalers and manufacturers and may participate in the 340B Prime Vendor Program (PVP). As the government's awarded 340B Prime Vendor, Apexus is responsible for securing sub-ceiling discounts on outpatient drug purchases and discounts on other pharmacy related products and services for covered entities electing to join the PVP. For complete information, see the Prime Vendor Program .
HRSA does not specify how participants should implement the 340B Program. As long as participants comply with all 340B Program requirements, they have flexibility in implementing the 340B Program.
Most covered entities choose one or more of the following options: